ALX-0651

· Ablynx (Sanofi)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALX-0651, covering 2012-04-17 to 2012-04-17. Get the full timeline:

Most recent: Clinical Trial Update: First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4 [Phase 1]